ALK inhibitors in non-small cell lung cancer: crizotinib and beyond.

The treatment of patients with advanced non-small cell lung cancer (NSCLC) harboring chromosomal rearrangements of anaplastic lymphoma kinase (ALK) has been revolutionized by the development of crizotinib, a small molecule inhibitor of the tyrosine kinases ALK, ROS1, and MET. Resistance to crizotinib invariably develops, however, through a variety of mechanisms. In the last few years, a flurry of new and more potent ALK inhibitors has emerged for the treatment of ALK-positive NSCLC, including ceritinib (LDK378), alectinib (RO5424802/CH5424802), AP26113, ASP3026, TSR-011, PF-06463922, RXDX-101, X-396, and CEP-37440. Cancers harboring ALK rearrangements may also be susceptible to treatment with heat shock protein 90 inhibitors. This review focuses on the pharmacologic and clinical properties of these compounds, either as monotherapies or in combination with other drugs. With so many ALK inhibitors in development, the challenges of how these agents should be studied and ultimately prescribed are also discussed.

[1]  Wei Zheng,et al.  A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. , 2011, Cancer research.

[2]  A. Isacchi,et al.  Abstract 2092: The ALK inhibitor NMS-E628 also potently inhibits ROS1 and induces tumor regression in ROS-driven models . , 2013 .

[3]  A. Sakamoto,et al.  Long-lasting response to crizotinib in brain metastases due to EML4-ALK-rearranged non-small-cell lung cancer , 2013, BMJ Case Reports.

[4]  F. Chibon,et al.  Identification of a Recurrent STRN/ALK Fusion in Thyroid Carcinomas , 2014, PloS one.

[5]  Jeffrey W. Clark,et al.  Efficacy and safety of crizotinib in patients with advanced ROS1-rearranged non-small cell lung cancer (NSCLC). , 2013 .

[6]  Murray Krahn,et al.  Cost effectiveness of EML4-ALK fusion testing and first-line crizotinib treatment for patients with advanced ALK-positive non-small-cell lung cancer. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  T. Clackson,et al.  Abstract LB-298: AP26113, a potent ALK inhibitor, overcomes mutations in EML4-ALK that confer resistance to PF-02341066 (PF1066) , 2010 .

[8]  Ryohei Katayama,et al.  Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK , 2011, Proceedings of the National Academy of Sciences.

[9]  J. Engelman,et al.  Ceritinib in ALK-rearranged non-small-cell lung cancer. , 2014, The New England journal of medicine.

[10]  M. Borrello,et al.  Cytogenetics and molecular genetics of carcinomas arising from thyroid epithelial follicular cells , 1996, Genes, chromosomes & cancer.

[11]  T. Clackson,et al.  Abstract 1794: AP26113 is a dual ALK/EGFR inhibitor: Characterization against EGFR T790M in cell and mouse models of NSCLC , 2012 .

[12]  A. Isacchi,et al.  Abstract A243: Characterization of NMS‐E628, a small molecule inhibitor of anaplastic lymphoma kinase with antitumor efficacy in ALK‐dependent lymphoma and non‐small cell lung cancer models , 2009 .

[13]  A. Atherly,et al.  The cost-effectiveness of screening lung cancer patients for targeted drug sensitivity markers , 2012, British Journal of Cancer.

[14]  Denis Maillet,et al.  Ineffectiveness of crizotinib on brain metastases in two cases of lung adenocarcinoma with EML4-ALK rearrangement. , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[15]  T. Clackson,et al.  First-in-human dose-finding study of the ALK/EGFR inhibitor AP26113 in patients with advanced malignancies: Updated results. , 2013 .

[16]  Jeffrey W. Clark,et al.  Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. , 2012, The Lancet. Oncology.

[17]  S. Lindquist,et al.  HSP90 and the chaperoning of cancer , 2005, Nature Reviews Cancer.

[18]  J. Maris,et al.  Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study. , 2013, The Lancet. Oncology.

[19]  T. Nakagawa,et al.  Ability of the Met Kinase Inhibitor Crizotinib and New Generation EGFR Inhibitors to Overcome Resistance to EGFR Inhibitors , 2013, PloS one.

[20]  L. Guerra,et al.  Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase-positive lymphoma patients. , 2014, Journal of the National Cancer Institute.

[21]  K. Robison,et al.  The Hsp90 inhibitor IPI-504 rapidly lowers EML4–ALK levels and induces tumor regression in ALK-driven NSCLC models , 2011, Oncogene.

[22]  S. Sleijfer,et al.  Anaplastic lymphoma kinase aberrations in rhabdomyosarcoma: clinical and prognostic implications. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  S. Ramalingam,et al.  Heat shock protein 90 inhibitors in non-small-cell lung cancer , 2014, Current opinion in oncology.

[24]  Sungjoon Kim,et al.  Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 , 2013, Journal of medicinal chemistry.

[25]  N. Hanna,et al.  MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling , 2008 .

[26]  Y. Ohe,et al.  CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study. , 2013, The Lancet. Oncology.

[27]  Michael Thomas,et al.  Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. , 2013, The New England journal of medicine.

[28]  Lucio Crinò,et al.  Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  Marc Ladanyi,et al.  Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. , 2010, The New England journal of medicine.

[30]  S. Perkins,et al.  ALK1 and p80 Expression and Chromosomal Rearrangements Involving 2p23 in Inflammatory Myofibroblastic Tumor , 2001, Modern Pathology.

[31]  Huaqing Zhao,et al.  Differential Inhibitor Sensitivity of Anaplastic Lymphoma Kinase Variants Found in Neuroblastoma , 2011, Science Translational Medicine.

[32]  Thomas J. Smith,et al.  Cost effectiveness of crizotinib for anaplastic lymphoma kinase-positive, non-small-cell lung cancer: who is going to blink at the cost? , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  N. Sach,et al.  Abstract PR10: Is CNS availability for oncology a no-brainer? Discovery of PF-06463922, a novel small molecule inhibitor of ALK/ROS1 with preclinical brain availability and broad spectrum potency against ALK-resistant mutations. , 2013 .

[34]  N. Hanna,et al.  EGF Receptor Gene Mutations Are Common in Lung Cancers From “Never Smokers” and Are Associated With Sensitivity of Tumors to Gefitinib and Erlotinib , 2006 .

[35]  Patricia L. Harris,et al.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.

[36]  P. Bunn,et al.  Resistance to ROS1 Inhibition Mediated by EGFR Pathway Activation in Non-Small Cell Lung Cancer , 2013, PloS one.

[37]  A. Shaw,et al.  Results of a global phase II study with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC). , 2012 .

[38]  Gudrun Schleiermacher,et al.  Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma , 2008, Nature.

[39]  Dara L Aisner,et al.  ROS1 and ALK Fusions in Colorectal Cancer, with Evidence of Intratumoral Heterogeneity for Molecular Drivers , 2013, Molecular Cancer Research.

[40]  Roman K. Thomas,et al.  Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors. , 2011, Cancer research.

[41]  M. Barbacid,et al.  A human oncogene formed by the fusion of truncated tropomyosin and protein tyrosine kinase sequences , 1986, Nature.

[42]  Peter G. Schultz,et al.  Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK , 2007, Proceedings of the National Academy of Sciences.

[43]  L. Urban,et al.  Major partial response to crizotinib, a dual MET/ALK inhibitor, in a squamous cell lung (SCC) carcinoma patient with de novo c-MET amplification in the absence of ALK rearrangement. , 2014, Lung cancer.

[44]  C. Messa,et al.  Crizotinib in anaplastic large-cell lymphoma. , 2011, The New England journal of medicine.

[45]  Sergei L Timofeevski,et al.  Abstract A277: PF-06463922, a novel ROS1/ALK inhibitor, demonstrates sub-nanomolar potency against oncogenic ROS1 fusions and capable of blocking the resistant ROS1G2032R mutant in preclinical tumor models. , 2013 .

[46]  Jeffrey W. Clark,et al.  Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. , 2011, The Lancet. Oncology.

[47]  Kol Jia Yong,et al.  Acquired resistance to crizotinib from a mutation in CD74-ROS1. , 2013, The New England journal of medicine.

[48]  Young Lim Choi,et al.  EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. , 2010, The New England journal of medicine.

[49]  S. Gabriel,et al.  EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.

[50]  D. Whittington,et al.  Abstract 1795: Characterization of a novel series of potent, selective inhibitors of wild type and mutant/fusion anaplastic lymphoma kinase , 2012 .

[51]  A. Iafrate,et al.  Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  G. Inghirami,et al.  CEP-28122, a Highly Potent and Selective Orally Active Inhibitor of Anaplastic Lymphoma Kinase with Antitumor Activity in Experimental Models of Human Cancers , 2011, Molecular Cancer Therapeutics.

[53]  Tatiana G. Kutateladze,et al.  Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non–Small Cell Lung Cancer , 2012, Clinical Cancer Research.

[54]  Jeffrey W. Clark,et al.  MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[55]  A. Iafrate,et al.  Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers , 2012, Science Translational Medicine.

[56]  A. Shaw,et al.  Clinical characteristics of ALK+ NSCLC patients (pts) treated with crizotinib beyond disease progression (PD): Potential implications for management. , 2012 .

[57]  L. Sequist,et al.  PHASE II ACTIVITY OF THE HSP90 INHIBITOR AUY922 IN PATIENTS WITH ALK-REARRANGED (ALK plus ) OR EGFR-MUTATED ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) , 2012 .

[58]  Iwei Yeh,et al.  Kinase fusions are frequent in Spitz tumours and spitzoid melanomas , 2014, Nature Communications.

[59]  S. Kobayashi,et al.  CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[60]  J. Cheville,et al.  ALK alterations in adult renal cell carcinoma: frequency, clinicopathologic features and outcome in a large series of consecutively treated patients , 2012, Modern Pathology.

[61]  Shibing Deng,et al.  Multiplexed deep sequencing analysis of ALK kinase domain identifies resistance mutations in relapsed patients following crizotinib treatment. , 2013, Genomics.

[62]  Sergei L Timofeevski,et al.  Abstract C253: PF-06463922, a novel brain-penetrating small molecule inhibitor of ALK/ROS1 with potent activity against a broad spectrum of ALK resistant mutations in preclinical models in vitro and in vivo. , 2013 .

[63]  S. Digumarthy,et al.  Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[64]  H. Aburatani,et al.  Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer , 2007, Nature.

[65]  Jeffrey W. Clark,et al.  Rapid radiographic and clinical improvement after treatment of a MET-amplified recurrent glioblastoma with a mesenchymal-epithelial transition inhibitor. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[66]  A. Shaw,et al.  Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer. , 2013, Cancer discovery.

[67]  L. Shun.  An Orally Available Small-Molecule Inhibitor of c-Met,PF-2341066,Exhibits Cytoreductive Antitumor Efficacy through Antiproliferative and Antiangiogenic Mechanisms , 2010 .

[68]  P. David Pearson,et al.  Phase 1 open label, dose escalation study of RXDX101, an oral pan-trk, ROS1, and ALK inhibitor, in patients with advanced solid tumors with relevant molecular alterations. , 2014 .

[69]  Juan J. Miret,et al.  Abstract 3623: Efficacy and pharmacodynamic analysis of AP26113, a potent and selective orally active inhibitor of Anaplastic Lymphoma Kinase (ALK) , 2010 .

[70]  W. Pao,et al.  Evolutionary Modeling of Combination Treatment Strategies To Overcome Resistance to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer , 2011, Molecular pharmaceutics.

[71]  L. Garraway,et al.  Oncogenic and drug sensitive NTRK1 rearrangements in lung cancer , 2013, Nature Medicine.

[72]  S. Kobayashi,et al.  Acquired Resistance to the ALK Inhibitor Crizotinib in the Absence of an ALK Mutation , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[73]  A. Isacchi,et al.  Abstract A232: In vitro and in vivo activity of NMS-E628 against ALK mutations resistant to Xalkori. , 2011 .

[74]  Hiroshi Sakamoto,et al.  CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant. , 2011, Cancer cell.

[75]  Chen-Hsiang Yeang,et al.  Impact of genetic dynamics and single-cell heterogeneity on development of nonstandard personalized medicine strategies for cancer , 2012, Proceedings of the National Academy of Sciences.

[76]  N. Socci,et al.  Optimization of Dosing for EGFR-Mutant Non–Small Cell Lung Cancer with Evolutionary Cancer Modeling , 2011, Science Translational Medicine.

[77]  A. Shaw,et al.  The central nervous system as a sanctuary site in ALK-positive non-small-cell lung cancer. , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[78]  Jeffrey W. Clark,et al.  Rapid and dramatic radiographic and clinical response to an ALK inhibitor (crizotinib, PF02341066) in an ALK translocation-positive patient with non-small cell lung cancer. , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[79]  W. Pao,et al.  A phase I trial of X-396, a novel ALK inhibitor, in patients with advanced solid tumors. , 2014 .

[80]  Tae Min Kim,et al.  Heterogeneity of Genetic Changes Associated with Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancer , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[81]  A. Tolcher,et al.  Pharmacokinetics and safety of an oral ALK inhibitor, ASP3026, observed in a phase I dose escalation trial. , 2013 .

[82]  K. Mori,et al.  The Selective Anaplastic Lymphoma Receptor Tyrosine Kinase Inhibitor ASP3026 Induces Tumor Regression and Prolongs Survival in Non–Small Cell Lung Cancer Model Mice , 2014, Molecular Cancer Therapeutics.

[83]  L. Neckers,et al.  The HSP90 inhibitor ganetespib synergizes with the MET kinase inhibitor crizotinib in both crizotinib-sensitive and -resistant MET-driven tumor models. , 2013, Cancer research.

[84]  A. Shaw,et al.  Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[85]  Jianyong Chen,et al.  LDK378: a promising anaplastic lymphoma kinase (ALK) inhibitor. , 2013, Journal of medicinal chemistry.

[86]  T. Clackson,et al.  Abstract 5655: AP26113 possesses pan-inhibitory activity versus crizotinib-resistant ALK mutants and oncogenic ROS1 fusions. , 2013 .

[87]  M. Ladanyi,et al.  ALK Rearrangements Are Mutually Exclusive with Mutations in EGFR or KRAS: An Analysis of 1,683 Patients with Non–Small Cell Lung Cancer , 2013, Clinical Cancer Research.

[88]  L. Tanoue,et al.  Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer , 2012 .

[89]  W. Guo,et al.  A Multicenter Phase II Study of Ganetespib Monotherapy in Patients with Genotypically Defined Advanced Non–Small Cell Lung Cancer , 2013, Clinical Cancer Research.

[90]  A. Tsao,et al.  ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers , 2012 .

[91]  Y. Ohe,et al.  A phase I/II study with a CNS-penetrant, selective ALK inhibitor alectinib in ALK-rearranged non-small cell lung cancer (ALK+ NSCLC) patients (pts): Updates on progression free survival (PFS) and safety results from AF-001JP. , 2015 .

[92]  S. Digumarthy,et al.  Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors , 2011, Science Translational Medicine.

[93]  Wei Zheng,et al.  The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers. , 2010, Cancer research.

[94]  H. Sakamoto,et al.  Design and synthesis of a highly selective, orally active and potent anaplastic lymphoma kinase inhibitor (CH5424802). , 2012, Bioorganic & medicinal chemistry.